Preview

Современная ревматология

Расширенный поиск

Интермиттирующая терапия остеопороза с помощью внутривенной формыибандроната

https://doi.org/10.14412/1996-7012-2008-490

Полный текст:

Аннотация

Последовательно рассмотрено внедрение интермиттирующего назначения ибандроната (И) с определением его однократной дозы и годовой кумулятивной дозы. Приведены данные о достаточной антирезорбтивной активности прерывистого курса лечения. Показана необходимость создания внутривенной формы препарата и подробно представлены данные об эффективности парентерального И, освещена возможность его применения при вторичном (стероидном) остеопорозе. Приведены доказательства уменьшения риска внепо-звоночньа и всех клинических переломов при внутривенном введении 3 мг И ежеквартально и пероральном приеме 150 мг ежемесячно.

Литература

1. <div><p>Lukert B.P., Raisz L.G. Glucocorticoid-induced osteoporosis. Рathogenesis and management. Ann Intern Med 1990; 112: 352-64.</p><p>Reid I.R. Glucocorticoid osteoporosis - mechanisms and management. Eur J Endocrinol 1997; 137: 209-17.</p><p>Hochberg M.C., Greenspan S., Wasnich R.D. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002; 87: 1586-92.</p><p>Bauss F., Wagner M., Hothorn L.H. Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats. J Rheumatol 2002; 29: 990-8.</p><p>Monier-Faugere M.C. et al. Anewbisphosphonate, BM21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs. J Bone Miner Res 1993; 8: 1345-55.</p><p>Smith S.Y. et al. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 2003; 32: 45-55.</p><p>Muller R. et al. Intermittent ibandronate preserves bone quality and bone strength in the lumbar spine after 16 months of treatment in the ovariec-tomized cynomolgus monkey. J Bone Miner 2004; 19: 1787-96.</p><p>Papapoulos S.E., Schimmer R.C. Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate.Ann Rheum Dis 2007; 66: 853-8.</p><p>Ravn P. et al. The effect on bone mass and bone markers of different doses of ibandronate: a new bis-phosphonate for prevention and treatment of post-menopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dosefinding study. Bone 1996; 19: 527-33.</p><p>Chesnut C.H. et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19: 1241-9.</p><p>Chesnut C.H. et al. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from</p><p>BONE. Curr Med Res Opin 2005; 21: 391-401.</p><p>Emkey R., Koltun W., Beusterien K. et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Bonviva Alendronate Trial in Osteoporosis. Curr Med Res Opin 2005; 21: 1895-903.</p><p>Miller P.D., McClung M., Macovei I. et al. Monthly oral ibandronate therapy in post-menopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005; 20: 1315-22.</p><p>Reginster J.-Y., Adami S., Lakatos P. et al. Efficacy and tolerability of once-monthly oral iban-dronate in postmenopausal osteoporosis: 2-year results from the MOBILE study. Ann Rheum Dis 2006; 65: 654-61.</p><p>Thiebaud D. et al. Three monthly intravenous injections of ibandronate in the treatment of post-menopausal osteoporosis. Am J Med 1997; 103: 298-307.</p><p>Recker R. et al. Insufficiently dosed intravenous ibandronate injections are Associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 2004; 34: 890-9.</p><p>Adami S. et al. Efficacy and safety of ibandronate given by intravenous Injection once every 3 months. Bone 2004; 34: 881-9.</p><p>Dellmas P.D. et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administrationstudy. Arthritis Rheum 2006; 54: 1838-46.</p><p>Civittelli R. et al. Continued improvements in bone mineral density in Women with postmenopausal osteoporosis following 1and 2years of intravenous Ibandronate therapy. J Bone Miner Res 2006; 21: 14-5.</p><p>Harris S.T, Barr C.E., Miller P.D. Ibandronate reduces clinical and non-vertebral fracture risk in women with postmenopausal osteoporosis (PMO): results of a pooled analysis of clinical trials. National Osteoporosis Foundation 2007; 7th International Symposiumon Osteoporosis.</p><p>Recker R., Stakkestad J.A., Chesnut C.H. et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 2004; 34: 890-9.</p><p>Adami S., Prince R., Halse J. et al. Two-year safety and tolerability profile of intravenous ibandronate injections: the DIVA study [abstract P258]. Osteoporos Int 2006; 17: 69.</p><p>Cranney A.G., Wells G.S., Adachi R. Non-vertebral fracturer eduction with high- versus low-dose ibandronate: a meta-analysis of individual patient data. Ann Rheum Dis 2007; 66: 681.</p><p>Ringe J.D., Dorst A., Faber H. et al. Three- monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis Rheumatology 2003; 42: 743-9.</p></div><br />


Для цитирования:


Алексеева Л.И., Alekseyeva L.I. Интермиттирующая терапия остеопороза с помощью внутривенной формыибандроната. Современная ревматология. 2008;2(3):55-59. https://doi.org/10.14412/1996-7012-2008-490

For citation:


Alekseeva L.I., Alekseyeva L.I. Intermittent intravenous ibandronate therapy for osteoporosis. Modern Rheumatology Journal. 2008;2(3):55-59. (In Russ.) https://doi.org/10.14412/1996-7012-2008-490

Просмотров: 525


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)